This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1/2/3 variant advanced solid tumors.
Age ≥ 18 years;
Histologically or cytologically confirmed unresectable advanced solid tumors with failure or intolerance to standard treatments;
At least one measurable lesion per RECIST v1.1 criteria;
Gene testing confirms FGFR1/2/3 variants, including but not limited to mutations, fusions/rearrangements in solid tumors;
Diagnosis of other malignancies within 3 years before the first dose, except for certain treated skin carcinomas and in-situ carcinomas;
Previous treatment with selective FGFR inhibitors;
Receipt of other investigational drugs within 21 days or antitumor drugs within 14 days before the first dose;
Unresolved toxicity from prior treatments unless ≤ Grade 1 or related to alopecia or fatigue;